Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 15/20 | 0.56 |
| ▸ | THRA | P10827 | 14/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520192 | 0.94 | THRA (0.62) | THRBTHRALMNAHTTSMN1; SMN2 | |
| SCHEMBL6522287 | 0.93 | THRB (0.57) | THRBTHRAMAPTNR3C1 | |
| SCHEMBL6513080 | 0.93 | THRB (0.55) | THRBTHRALMNAHTTSMN1; SMN2 | |
| SCHEMBL6522316 | 0.92 | SMN1; SMN2 (0.49) | THRBTHRALMNAHTTSMN1; SMN2 | |
| SCHEMBL6516969 | 0.90 | THRA (0.58) | THRBTHRALMNAHTTSMN1; SMN2 | |
| SCHEMBL6520233 | 0.90 | THRB (0.56) | THRBTHRALMNAHTTSMN1; SMN2 | |
| SCHEMBL6516475 | 0.88 | THRA (0.46) | THRBTHRALMNAHTTSMN1; SMN2 | |
| SCHEMBL6514238 | 0.88 | SMN1; SMN2 (0.48) | THRBTHRALMNAHTTSMN1; SMN2 | |
| SCHEMBL6515704 | 0.88 | THRB (0.55) | THRBTHRALMNAHTTSMN1; SMN2 | |
| SCHEMBL6862290 | 0.87 | THRB (0.62) | THRBTHRALMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | THRB 1772/4885THRA 2460/4885LMNA 3113/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | THRB 1835/4885THRA 1917/4885LMNA 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.